251 related articles for article (PubMed ID: 27847320)
1. Inhibition of CDK9 induces apoptosis and potentiates the effect of cisplatin in hypopharyngeal carcinoma cells.
Cao S; Yu Y; Chen S; Lei D; Wang S; Pan X; Peng J
Biochem Biophys Res Commun; 2017 Jan; 482(4):536-541. PubMed ID: 27847320
[TBL] [Abstract][Full Text] [Related]
2. Co-targeting PI3K/Akt and MAPK/ERK pathways leads to an enhanced antitumor effect on human hypopharyngeal squamous cell carcinoma.
Peng X; Liu Y; Zhu S; Peng X; Li H; Jiao W; Lin P; Zhang Z; Qiu Y; Jin M; Wang R; Kong D
J Cancer Res Clin Oncol; 2019 Dec; 145(12):2921-2936. PubMed ID: 31620898
[TBL] [Abstract][Full Text] [Related]
3. CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia.
Rahaman MH; Yu Y; Zhong L; Adams J; Lam F; Li P; Noll B; Milne R; Peng J; Wang S
Invest New Drugs; 2019 Aug; 37(4):625-635. PubMed ID: 30194564
[TBL] [Abstract][Full Text] [Related]
4. PHF20 inhibition promotes apoptosis and cisplatin chemosensitivity via the OCT4‑p‑STAT3‑MCL1 signaling pathway in hypopharyngeal squamous cell carcinoma.
Liu X; Zhang Z; Kan S; Lv Z; Zhou S; Liu X; Jing P; Xu W
Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 33982773
[TBL] [Abstract][Full Text] [Related]
5. Targeting CDK9 for treatment of colorectal cancer.
Rahaman MH; Lam F; Zhong L; Teo T; Adams J; Yu M; Milne RW; Pepper C; Lokman NA; Ricciardelli C; Oehler MK; Wang S
Mol Oncol; 2019 Oct; 13(10):2178-2193. PubMed ID: 31398271
[TBL] [Abstract][Full Text] [Related]
6. Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73.
Lam F; Abbas AY; Shao H; Teo T; Adams J; Li P; Bradshaw TD; Fischer PM; Walsby E; Pepper C; Chen Y; Ding J; Wang S
Oncotarget; 2014 Sep; 5(17):7691-704. PubMed ID: 25277198
[TBL] [Abstract][Full Text] [Related]
7. Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.
Tanaka N; Patel AA; Wang J; Frederick MJ; Kalu NN; Zhao M; Fitzgerald AL; Xie TX; Silver NL; Caulin C; Zhou G; Skinner HD; Johnson FM; Myers JN; Osman AA
Clin Cancer Res; 2015 Nov; 21(21):4831-44. PubMed ID: 26124202
[TBL] [Abstract][Full Text] [Related]
8. A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine.
Walsby E; Pratt G; Shao H; Abbas AY; Fischer PM; Bradshaw TD; Brennan P; Fegan C; Wang S; Pepper C
Oncotarget; 2014 Jan; 5(2):375-85. PubMed ID: 24495868
[TBL] [Abstract][Full Text] [Related]
9. In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83.
Liu X; Lam F; Shi S; Fischer PM; Wang S
Invest New Drugs; 2012 Jun; 30(3):889-97. PubMed ID: 21331744
[TBL] [Abstract][Full Text] [Related]
10. Targeting MCL-1 sensitizes human esophageal squamous cell carcinoma cells to cisplatin-induced apoptosis.
Yu X; Li W; Xia Z; Xie L; Ma X; Liang Q; Liu L; Wang J; Zhou X; Yang Y; Liu H
BMC Cancer; 2017 Jun; 17(1):449. PubMed ID: 28659182
[TBL] [Abstract][Full Text] [Related]
11. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
[TBL] [Abstract][Full Text] [Related]
12. CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol.
Liu X; Shi S; Lam F; Pepper C; Fischer PM; Wang S
Int J Cancer; 2012 Mar; 130(5):1216-26. PubMed ID: 21484792
[TBL] [Abstract][Full Text] [Related]
13. Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.
Yeh YY; Chen R; Hessler J; Mahoney E; Lehman AM; Heerema NA; Grever MR; Plunkett W; Byrd JC; Johnson AJ
Oncotarget; 2015 Feb; 6(5):2667-79. PubMed ID: 25596730
[TBL] [Abstract][Full Text] [Related]
14. microRNA-504 inhibits cancer cell proliferation via targeting CDK6 in hypopharyngeal squamous cell carcinoma.
Kikkawa N; Kinoshita T; Nohata N; Hanazawa T; Yamamoto N; Fukumoto I; Chiyomaru T; Enokida H; Nakagawa M; Okamoto Y; Seki N
Int J Oncol; 2014 Jun; 44(6):2085-92. PubMed ID: 24647829
[TBL] [Abstract][Full Text] [Related]
15. FoxM1 overexpression promotes cell proliferation and migration and inhibits apoptosis in hypopharyngeal squamous cell carcinoma resulting in poor clinical prognosis.
Chen Y; Liu Y; Ni H; Ding C; Zhang X; Zhang Z
Int J Oncol; 2017 Oct; 51(4):1045-1054. PubMed ID: 28848994
[TBL] [Abstract][Full Text] [Related]
16. Elevated O-GlcNAcylation Promotes Malignant Phenotypes of Hypopharyngeal Squamous Cell Carcinoma by Stabilizing Nrf2 through Regulation of the PI3K/Akt Pathway.
Dai W; Jin X; Jiang B; Chen W; Ji Z; Xu X; Tang M; Dai K; Han L
Anticancer Agents Med Chem; 2020; 20(16):1933-1942. PubMed ID: 32538734
[TBL] [Abstract][Full Text] [Related]
17. A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies.
Phillips DC; Jin S; Gregory GP; Zhang Q; Xue J; Zhao X; Chen J; Tong Y; Zhang H; Smith M; Tahir SK; Clark RF; Penning TD; Devlin JR; Shortt J; Hsi ED; Albert DH; Konopleva M; Johnstone RW; Leverson JD; Souers AJ
Leukemia; 2020 Jun; 34(6):1646-1657. PubMed ID: 31827241
[TBL] [Abstract][Full Text] [Related]
18. A novel kinase inhibitor, LZT-106, downregulates Mcl-1 and sensitizes colorectal cancer cells to BH3 mimetic ABT-199 by targeting CDK9 and GSK-3β signaling.
Yu Z; Du J; Zhao Y; Gao Y; Li Y; Zhao K; Lu N
Cancer Lett; 2021 Feb; 498():31-41. PubMed ID: 33129955
[TBL] [Abstract][Full Text] [Related]
19. Chloroquine-enhanced efficacy of cisplatin in the treatment of hypopharyngeal carcinoma in xenograft mice.
Zhao XG; Sun RJ; Yang XY; Liu DY; Lei DP; Jin T; Pan XL
PLoS One; 2015; 10(4):e0126147. PubMed ID: 25923669
[TBL] [Abstract][Full Text] [Related]
20. CDK9 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression.
Mitra P; Yang RM; Sutton J; Ramsay RG; Gonda TJ
Oncotarget; 2016 Feb; 7(8):9069-83. PubMed ID: 26812885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
